Dyne Therapeutics, Inc.

NasdaqGS:DYN Stok Raporu

Piyasa değeri: US$2.9b

Dyne Therapeutics Yönetim

Yönetim kriter kontrolleri 2/4

Dyne Therapeutics CEO'su John Cox, Mar2024 tarihinde atandı, in görev süresi bir yıldan az. şirketin hisselerinin 0.037% doğrudan sahiptir ve bu hisselerin değeri $ 1.06M dir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 3.4 yıl ve 5 yıldır.

Anahtar bilgiler

John Cox

İcra Kurulu Başkanı

n/a

Toplam tazminat

CEO maaş yüzdesin/a
CEO görev süresiless than a year
CEO sahipliği0.04%
Yönetim ortalama görev süresi3.4yrs
Yönetim Kurulu ortalama görev süresi5yrs

Son yönetim güncellemeleri

Recent updates

Dyne Therapeutics: Management Merry-Go-Round, Shaky Data Rock Wall Street

Sep 04

Companies Like Dyne Therapeutics (NASDAQ:DYN) Are In A Position To Invest In Growth

Aug 14
Companies Like Dyne Therapeutics (NASDAQ:DYN) Are In A Position To Invest In Growth

Dyne Therapeutics: Progress Undenied In DM1 And DMD Trials

May 21

We're Not Very Worried About Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Rate

May 04
We're Not Very Worried About Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Rate

Dyne: H2 2024 Muscle Disease Data Could Boost Value

Mar 05

We're Keeping An Eye On Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Rate

Dec 05
We're Keeping An Eye On Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Rate

Here's Why We're Watching Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Situation

Aug 09
Here's Why We're Watching Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Situation

We're Keeping An Eye On Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Rate

Mar 26
We're Keeping An Eye On Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Rate

We Think Dyne Therapeutics (NASDAQ:DYN) Needs To Drive Business Growth Carefully

Dec 10
We Think Dyne Therapeutics (NASDAQ:DYN) Needs To Drive Business Growth Carefully

Is Dyne Therapeutics (NASDAQ:DYN) In A Good Position To Invest In Growth?

Aug 26
Is Dyne Therapeutics (NASDAQ:DYN) In A Good Position To Invest In Growth?

Dyne wins regulatory nod to start trial for myotonic dystrophy candidate

Jul 12

Dyne stock rises 12% as FDA lifts hold on starting muscle disorder study of DYNE-251

Jul 05

Here's Why We're Watching Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Situation

May 05
Here's Why We're Watching Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Situation

We're Hopeful That Dyne Therapeutics (NASDAQ:DYN) Will Use Its Cash Wisely

Jan 12
We're Hopeful That Dyne Therapeutics (NASDAQ:DYN) Will Use Its Cash Wisely

We Think Dyne Therapeutics (NASDAQ:DYN) Can Afford To Drive Business Growth

Sep 29
We Think Dyne Therapeutics (NASDAQ:DYN) Can Afford To Drive Business Growth

Dyne Therapeutics' chief scientific officer Romesh Subramanian steps down

Jun 02

Here's Why We're Not Too Worried About Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Situation

May 12
Here's Why We're Not Too Worried About Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Situation

Dyne Therapeutics EPS beats by $0.10

May 06

Could The Dyne Therapeutics, Inc. (NASDAQ:DYN) Ownership Structure Tell Us Something Useful?

Jan 27
Could The Dyne Therapeutics, Inc. (NASDAQ:DYN) Ownership Structure Tell Us Something Useful?

CEO

John Cox (61 yo)

less than a year

Görev süresi

Mr. John G. Cox, M.B.A. serves as Chief Executive Officer, President and Director at Dyne Therapeutics, Inc. from March 2024. He also serves as Atlas Advisor at Atlas Venture L.P. since 2024. He serves as...


Liderlik Ekibi

İsimPozisyonGörev süresiTazminatSahiplik
John Cox
CEO, President & Directorless than a yearVeri yok0.037%
$ 1.1m
Romesh Subramanian
Co-Founder & Advisorno dataUS$4.37mVeri yok
Richard Scalzo
Senior VP and Head of Finance & Administration4.3yrsVeri yok0.0030%
$ 86.0k
John Najim
Chief Technical Officer1.6yrsVeri yokVeri yok
Oxana Beskrovnaya
Chief Scientific Officer3.4yrsUS$1.49m0.030%
$ 871.1k
Amy Reilly
Senior VP and Head of Corporate Communications & Investor Relations4.3yrsVeri yokVeri yok
Daniel Wilson
Senior VP & Head of Legal4.4yrsVeri yokVeri yok
Lucia Celona
Chief Human Resource Officerless than a yearVeri yokVeri yok
Debra Feldman
Chief Regulatory Affairs Officer4.5yrsVeri yokVeri yok
Ashish Dugar
Chief Medical Affairs Officer3.8yrsVeri yokVeri yok
Johanna Friedl-Naderer
Chief Commercial Officerless than a yearVeri yokVeri yok
Douglas Kerr
Chief Medical Officerless than a yearVeri yokVeri yok

3.4yrs

Ortalama Görev Süresi

56.5yo

Ortalama Yaş

Deneyimli Yönetim: DYN 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 3.4 yıldır).


Yönetim Kurulu Üyeleri

İsimPozisyonGörev süresiTazminatSahiplik
John Cox
CEO, President & Directorless than a yearVeri yok0.037%
$ 1.1m
Sudhir Agrawal
Member of Scientific Advisory Boardno dataVeri yokVeri yok
Edward Hurwitz
Independent Director6yrsUS$250.17k0%
$ 0
David Lubner
Independent Director4.7yrsUS$264.17k0.053%
$ 1.5m
Jason Rhodes
Independent Chairman6.9yrsUS$283.17k0%
$ 0
Dirk Kersten
Independent Director6yrsUS$262.67k0%
$ 0
Francesco Muntoni
Member of Scientific Advisory Board4.3yrsVeri yokVeri yok
Louis Kunkel
Member of Scientific Advisory Boardno dataVeri yokVeri yok
Nancy Andrews
Member of Scientific Advisory Boardno dataVeri yokVeri yok
Catherine Stehman-Breen
Independent Director5.4yrsUS$253.92k0.089%
$ 2.6m
Charles Thornton
Member of Scientific Advisory Boardno dataVeri yokVeri yok
Jeffrey Statland
Member of Scientific Advisory Board4.5yrsVeri yokVeri yok

5.0yrs

Ortalama Görev Süresi

61yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: DYN 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 5 yıldır).